SOURCE: Daxor Corp.

October 26, 2007 10:00 ET

Daxor Corporation Announces Queen's Medical Center of Honolulu, HI Purchases Second Blood Volume Analyzer

NEW YORK, NY--(Marketwire - October 26, 2007) - Daxor Corporation (AMEX: DXR), a medical instrumentation and biotechnology company, today announced receipt of a signed purchase agreement from the Queen's Medical Center in Honolulu, Hawaii for its second Blood Volume Analyzer BVA-100.

Dr. Mihae Yu, Professor of Surgery and Program Director of Surgical Critical Care, said that, "I have found blood volume measurements to be extremely useful in guiding both fluid and red cell replacement. Approximately one third of the time our clinical criteria, combining physical exam, clinical information, laboratory data and chest x-ray, may be misleading in terms of the intravascular volume status. Traditional methods of guessing intravascular volume status is particularly difficult in edematous patients post shock resuscitation. Also, we may be over as well as under-transfusing blood cells when using hematocrit as a guide, since hematocrit values may not reflect red cell volume. We need to study blood volume measurements further and determine its impact on patient outcomes. However, I have found the BVA-100 to be clinically useful as to warrant a second unit."

An October 17, 2007 Wall Street Journal article titled "Hospitals Combat an Insidious Complication" discusses how many hospitals are trying new strategies to combat permanent loss of memory and cognition in critical care patients. Inadequate oxygen delivery to the brain due to unrealized blood loss (blood volume) is a recognized cause of this kind of permanent brain damage. Previously reported clinical studies from Queen's Medical Center demonstrate how a measured intravascular blood volume provides a more accurate guide to recognizing and treating critical care patients who require a blood transfusion. Queen's Medical Center is one of the leading hospitals in the United States that routinely utilizes the BVA-100 for their critical care patients.

Daxor's goal is to help improve patient outcomes and reduce the cost of care through the diagnostic tool of an intravascular blood volume measurement. Daxor Corporation manufactures and markets the BVA-100, a semi-automated, FDA approved Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex, a single use diagnostic kit. The BVA-100 measures intravascular blood volume to within a 98% accuracy. More information about the BVA-100 and Volumex can be found at

Contact Information

  • Contact Information:

    Stephen Feldschuh
    Chief Operating Officer
    Email Contact


    Diane Meegan
    Investor Relations
    Email Contact.